S. Tutchko

Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies

M. Fakih, M. Egorin, S. Strychor, 2005, Cancer Chemotherapy and Pharmacology.

Phase I Pharmacokinetic-Pharmacodynamic Study of 17-(Allylamino)-17-Demethoxygeldanamycin (17AAG, NSC 330507), a Novel Inhibitor of Heat Shock Protein 90, in Patients with Refractory Advanced Cancers

E. Zuhowski, M. Egorin, D. Trump, 2005, Clinical Cancer Research.

A phase I pharmacokinetic (PK) and pharmacodynamic (PD) trial of weekly 17-allylamino-17 demethoxygeldanamycin (17AAG, NSC-704057) in patients with advanced tumors.

E. Zuhowski, D. Trump, C. Belani, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.